CLAIM AMENDMENTS


Listing of Claims:

Claims 1-23 (canceled)

Claims 24-33 (canceled)

Claim 34 (not entered)

Claim 35 (new): A macrocyclic compound of the formula (1):



and it's pharmaceutically acceptable salts,

wherein

Fragment A₁ is:

(1-i)

wherein

Y is selected from the group consisting of

H,
$$H_3C$$
, O_2N

,
$$O_2N$$
 and O_2N O

 X_1 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_1 is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;

when X_1 is $\,$ -CH-, R_1 is a radical independently selected from the group consisting of

Fragment A₂ is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline; or

(2-ii)

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

$$H$$
 X_2
 R_2

 X_2 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_2 is -(CH₂)₂- or -(CH₂)₃-, R₂ is absent;

when X_2 is $\,$ -CH-, R_2 is a radical independently selected from the group consisting of

Fragment A₃ is:

(3-i) *D*-proline, *L*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline; or

(3-ii)

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

$$H_{N}$$
 X_{3}
 R_{3}

 X_3 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_3 is -(CH₂)₂- or -(CH₂)₃-, R₃ is absent;

when X_3 is $\,$ -CH-, R_3 is a radical independently selected from the group consisting of

 W_1 to W_{16} are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

Fragment T is a radical selected from the group consisting of:

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }


Serial No. 09/679,331

wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 36 (new): A macrocyclic compound of the formula (1):

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331



and it's pharmaceutically acceptable salts,

wherein

Fragment A₁ is:

(1-i)

wherein

Y is selected from the group consisting of

H ,
$$O_2N$$

,
$$O_2N$$
 and O_2N and O_2N

 X_1 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_1 is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

when X_1 is $\,$ -CH-, R_1 is a radical independently selected from the group consisting of

Fragment A₂ is:

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline; or

(2-ii)


$$H_{N_2}$$

wherein

 X_2 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_2 is -(CH₂)₂- or -(CH₂)₃-, R₂ is absent;

when X_2 is $\,$ -CH-, R_2 is a radical independently selected from the group consisting of



Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline; or

(3-ii)


{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

$$R_3$$

 X_3 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_3 is -(CH₂)₂- or -(CH₂)₃-, R₃ is absent;

when X_3 is $\,$ -CH-, R_3 is a radical independently selected from the group consisting of



 $$W_{1}$$ to $\ensuremath{W_{16}}$ are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }


Fragment T is a radical selected from the group consisting of:

wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 37 (new): A macrocyclic compound of the formula (1):

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

Serial No. 09/679,331



and it's pharmaceutically acceptable salts,

wherein

Fragment A₁ is:

(1-i)


$$H$$
 X_1
 R_1

wherein

 X_1 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_1 is -(CH₂)₂- or -(CH₂)₃-, R_1 is absent;

when X_1 is $\,$ -CH-, R_1 is a radical independently selected from the group consisting of:



Fragment A₂ is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or (2-ii)


{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

$$R_2$$

 X_2 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_2 is -(CH₂)₂- or -(CH₂)₃-, R₂ is absent;

when X_2 is $\,$ -CH-, R_2 is a radical independently selected from the group consisting of



Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or (3-ii)

$$H_{N}$$
 X_{3}
 R_{3}

 X_3 is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X_3 is -(CH₂)₂- or -(CH₂)₃-, R₃ is absent;

when X_3 is $\,$ -CH-, R_3 is a radical independently selected from the group consisting of

Fragment T is a radical selected from the group consisting of:

{W:\06670\000H748-000\00080988.DOC *06670000H748-000* }

wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).